Galena halts clinical trial

Galena Biopharma Inc. (Nasdaq: GALE) will discontinue its Phase 3 PRESENT clinical trial due to futility. Shares of the biopharmaceutical plummeted $1.68 to close at $0.35.



Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.